Rapport Therapeutics (RAPP) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 10, 2026, to be held virtually, with voting available online, by phone, mail, or QR code until June 9, 2026.

• Stockholders as of April 14, 2026, are eligible to vote on director elections and auditor ratification.

• Proxy materials are distributed electronically to conserve resources and reduce costs.

Voting matters and shareholder proposals

• Proposal 1: Election of three Class II directors (James Healy, Robert J. Perez, Raymond Sanchez) for terms expiring in 2029.

• Proposal 2: Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.

• Board recommends voting FOR both proposals; plurality required for director election, majority for auditor ratification.

• Procedures for shareholder proposals and nominations for the 2027 meeting are outlined, with specific deadlines.

Board of directors and corporate governance

• Board consists of nine members divided into three staggered classes, with annual elections for one class.

• Majority of directors are independent; only the CEO is not considered independent.

• Board committees include audit, compensation, nominating and corporate governance, and science and technology, each with defined charters and independent membership.

• Board leadership structure separates the roles of chair and CEO.

• Directors are expected to attend at least 75% of meetings and annual meetings of stockholders.